title: Effect of 6'-acetylpaeoniflorin on dinitrochlorobenzene-induced allergic contact dermatitis in BALB/c mice.
abstract: Allergic contact dermatitis (ACD) is a classical experimental model of allergic inflammatory skin disease, which is a delayed-type hypersensitivity reaction that is mediated by hapten-specific T lymphocytes. The goal of this study was to investigate the pharmacokinetic profiles of 6'-acetylpaeoniflorin (6-AP) and the effect of 6-AP on the ACD model. 6-AP was synthesized from paeoniflorin (Pae) via acetylation, and the structure was confirmed. There were statistically significant differences in the pharmacokinetic parameters including t 1/2α , t 1/2β , AUC, MRT and C max among the animals that were orally administered Pae and 6-AP. An ACD model was induced using immunization with dinitrochlorobenzene (DNCB) in BALB/c mice. The mice were orally administered 6-AP (35, 70 and 140 mg/kg/d), Pae (70 mg/kg/d) and prednisone (Pre, 5 mg/kg/d) from day 1 to day 7 after immunization. The results indicated that the topical application of DNCB to the skin provoked obvious inflammatory responses. 6-AP significantly inhibited ear swelling and decreased inflammatory cell infiltration and epidermal keratinization. Additionally, 6-AP observably alleviated the hyperplasia of red pulp and germinal center appearance, decreased the spleen index and inhibited splenocyte proliferation in the ACD model compared to that of Pae. Furthermore, the study indicated that 6-AP could increase the IL-10 level, while simultaneously reducing the IL-17 level in splenocytes. In summary, these results suggest that 6-AP has a significantly higher anti-inflammatory effect than Pae and that 6-AP might be a candidate for the treatment of allergic skin diseases.
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Zhou
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: Xiaodan
authors.initials: X
authors.lastname: Yang
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: Xiaoyi
authors.initials: X
authors.lastname: Jia
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: James
authors.initials: J
authors.lastname: Asenso
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xiao
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China. wangchun533@126.com.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China. wangchun533@126.com.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China. wangchun533@126.com.
authors.forename: Chun
authors.initials: C
authors.lastname: Wang
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China. wwei@ahmu.edu.cn.|Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei, 230032, China. wwei@ahmu.edu.cn.|Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China. wwei@ahmu.edu.cn.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D002478:Cells, Cultured; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy*; D004137:Dinitrochlorobenzene; D005960:Glucosides / Q000138:chemical synthesis / Q000627:therapeutic use*; D006968:Hypersensitivity, Delayed; D016753:Interleukin-10 / Q000378:metabolism; D020381:Interleukin-17 / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D039821:Monoterpenes / Q000138:chemical synthesis / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects* / Q000276:immunology; D013154:Spleen / Q000276:immunology / Q000473:pathology*; D006027:Glycosides
chemical_list: D000893:Anti-Inflammatory Agents; D004137:Dinitrochlorobenzene; D005960:Glucosides; D016753:Interleukin-10; D020381:Interleukin-17; D039821:Monoterpenes; C000625444:6'-acetylpaeoniflorin; C015423:peoniflorin; D006027:Glycosides
keywords: 6′-Acetylpaeoniflorin (6-AP); Allergic contact dermatitis (ACD); Anti-inflammatory activity; Paeoniflorin (Pae); Pharmacokinetics